Acute Withdrawal From Smoked Cocaine - 9

Acute Withdrawal From Smoked Cocaine

NCT00000292•National Institute on Drug Abuse (NIDA)

View on ClinicalTrials.gov

Summary

The purpose of this study is to develop an experimental paradigm to examine acute withdrawal symptoms from cocaine.

Detailed Description

Although there are clearly identifiable withdrawal syndromes following cessation of a number of abused drugs such as alcohol and heroin, it is unclear whether a withdrawal syndrome follows the cessation of crack cocaine. A laboratory model of withdrawal from smoked (crack) cocaine would provide a safe and systematic method of testing the efficacy of behavioral or pharmacological treatments for withdrawal symptoms following cocaine smoking cessation. Therefore, this study investigated acute behavioral, subjective, and physiological withdrawal symptomatology for 6 hrs following 7 deliveries of 2 dose sized (0.07 vs. 0.4 mg/kg) of smoked cocaine. The behavioral measure was performance on a computerized reaction time task, subjective measures included participant and observer ratings of mood and withdrawal symptomatology, and physiological measures comprised heart rate and blood pressure. It was hypothesized that signs and symptoms of withdrawal from smoked cocaine would be greater following the 0.4 mg/kg dose size, compared to the 0.07 mg/kg dose size.

Eligibility

Age

21 - 45 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•M/F ages 21-45 with a history of smoked cocaine use at least twice a week for the past six months, including 0.5 g of cocaine in a 24hr period on at least one occasion. In good health as evidenced by physical exam and complete blood count, chest X-ray and electrolyte and liver function tests, with a normal resting 12-lead electrocardiograph (ECG) and blood pressure of less than 140/90 mmHg. Using an acceptable method of birth control. Having a urine toxicology screen positive for cocaine metabolites.

Exclusion Criteria

•Any DSM-IV Axis I disorder other than cocaine abuse or dependence, or dependence or daily use of psychoactive drugs other than nicotine or caffeine. A history of violence and/or currently on probation, parole or awaiting trial. Pregnant as determined by serum pregnancy screen, lactating or having delivered a child in the past 12 months. Seropositive tests for the human immunodeficiency virus (HIV) or hepatitis B. History of seizure disorder.

Locations (1)

University of Minnesota

Minneapolis, Minnesota, United States

Key Dates

Start Date

April 1, 1996

Completion Date

December 1, 2001

Last Updated

January 12, 2017

Conditions

Cocaine-Related DisordersSubstance Withdrawal SyndromeSubstance-Related Disorders

Interventions

Cocaine

PROCEDURE

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

NCT06676059

AlcoholismSubstance-Related Disorders

View study

RECRUITING

Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma

NCT07330349

Abdominal InjuriesAlcohol Intoxication+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acute Withdrawal From Smoked Cocaine - 9

Inclusion Criteria

Exclusion Criteria

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

GLP-1R Agonist Treatment for Opioid Use Disorder

Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder